

THURSDAY

THURSDAY, MAY 2, 2019: DAY 1

- 8:00 - 8:30** **REGISTRATION AND BREAKFAST**
- 8:30 - 8:45** **INTRODUCTIONS AND WELCOME**
- 8:45 - 10:20** **SESSION I: LABORATORY MODELS OF NETS**
- 8:45 - 8:50** **SESSION INTRODUCTION**
Chair/Panel Moderator
Daniel Chung, MD
Co-Chair, NETRF Board of Scientific Advisors
- 8:50 - 9:05** **MODELING NEUROENDOCRINE NEOPLASMS USING ADULT STEM CELL-DERIVED ORGANOIDs**
Talya Dayton, PhD (Hans Clevers Lab)
Hubrecht Institute, The Netherlands
- 9:05 - 9:20** **DEVELOPMENT OF EX-VIVO MODELS OF METASTATIC NEUROENDOCRINE TUMOURS**
Raj Srirajaskanthan, PhD
Kings College London, United Kingdom
- 9:20 - 9:35** **DEVELOPMENT OF 3D MODELS FOR NEUROENDOCRINE TUMORS**
Charlotte Kuperwasser, PhD
Tufts School of Medicine, Boston MA
- 9:35 - 9:45** **DISSECTING LYSINE METHYLTRANSFERASE SIGNALING IN PANCREATIC NEUROENDOCRINE TUMORS**
Pawel Mazur, PhD
University of Texas MD Anderson Cancer Center, Houston TX
- 9:45 - 10:05** **PARTNERING WITH PATIENTS TO CREATE A NEUROENDOCRINE TUMOR DEPENDENCY MAP**
Jesse Boehm, PhD
Broad Institute, Cambridge MA
- 10:05 - 10:20** **Q AND A DISCUSSION**
- 10:20 - 11:00** **COFFEE BREAK**
- 11:00 - 12:00** **SESSION II: IMMUNO-ONCOLOGY AND NETS**
- 11:00 - 11:05** **SESSION INTRODUCTION**
Chair/Panel Moderator
George Fisher, MD PhD
Co-Chair, NETRF Board of Scientific Advisors

- 11:05 – 11:20** **SINGLE DOMAIN ANTIBODY-DIRECTED CAR T CELLS POTENTLY SUPPRESS NEUROENDOCRINE TUMORS IN PRECLINICAL MODELS**
Xianxin Hua, MD PhD
University of Pennsylvania, Philadelphia PA
- 11:20 – 11:35** **SYSTEMATIC EVALUATION OF THE IMMUNE ENVIRONMENT OF NEUROENDOCRINE TUMOURS**
Chrissie Thirlwell, MD PhD FRCP (Presenting for Tim Meyer MRCP PhD)
University College London, United Kingdom
- 11:35 – 11:45** **NOVEL ANTIBODY-DRUG CONJUGATE (ADC) FOR PANCREATIC NEUROENDOCRINE TUMOR (PNET) TARGETED THERAPY**
Renata Jaskula-Sztul, PhD
The University of Alabama at Birmingham
- 11:45 – 12:00** **Q AND A DISCUSSION**
- 12:00 – 1:30** **LUNCH**
- 1:30 – 2:40** **SESSION III: DETECTING AND TARGETING NETS**
- 1:30 – 1:35** **SESSION INTRODUCTION**
Chair/Panel Moderator
Evan Vosburgh, MD
NETRF Board of Scientific Advisors
- 1:35 – 1:50** **A NOVEL APPROACH FOR PET IMAGING OF NEUROENDOCRINE TUMORS**
Babak Behnam Azad, PhD
Johns Hopkins School of Medicine, Baltimore MD
- 1:50 – 2:05** **SOMATOSTATIN RECEPTOR LIGANDS CAN BE USED TO IMAGE AND TREAT MURINE PNETS INDUCED BY MEN1-LOSS**
Brian Untch, MD
Memorial Sloan Kettering Cancer Center, New York NY
- 2:05 – 2:15** **NETCURE—SHINE NEW LIGHT ON NEUROENDOCRINE TUMOR THERAPY**
Martin Gotthardt, MD
Radboud University Nijmegen Medical Centre, The Netherlands
- 2:15 – 2:25** **FUNCTIONALIZED SILICA NANOPARTICLES: DEVELOPMENT OF A COMBINED PET AND TAT THERANOSTIC AGENT FOR NEUROENDOCRINE TUMORS**
Tara Mastren, PhD
University of Utah, Salt Lake City UT
- 2:25 – 2:40** **Q AND A DISCUSSION**
- 2:40 – 3:00** **COFFEE BREAK**

THURSDAY/FRIDAY

- 3:00 – 4:40** **SESSION IV: ADVANCES IN NET TREATMENT: NUCLEAR MEDICINE**
- 3:00 – 3:05** **SESSION INTRODUCTION**
Chair/Panel Moderator
Lisa Bodei, MD PhD
NETRF Board of Scientific Advisors
- 3:05 – 3:20** **DEVELOPING NOVEL COMBINATION THERAPIES FOR USE WITH 177LU-OCTREOTATE PRRT IN NETS, FOCUSING ON DNA-REPAIR MECHANISMS**
Rodney Hicks, MD
University of Melbourne, Australia
- 3:20 – 3:35** **SIMULTANEOUS AUGER E- AND B⁻-PARTICLE THERAPY OF METASTASIZED NET USING 161TB-DOTATOC**
Cristina Muller, PD Dr (Roger Schibli Lab)
Paul Scherrer Institut, Switzerland
- 3:35 – 3:45** **EVALUATION OF 225AC-DOTATATE FOR TREATMENT OF LUNG CARCINOID TUMORS**
David Morse, PhD
H. Lee Moffitt Cancer Center and Research Institute, Tampa FL
- 3:45 – 3:55** **NOVEL RADIOLIGANDS TO IMPROVE RADIOTHERAPY OF NEUROENDOCRINE TUMORS**
Kuo-Shyan Lin, PhD
British Columbia Cancer Agency Branch, Canada
- 3:55 – 4:20** **ADVANCEMENTS IN THERANOSTICS FOR NETS - NEW PEPTIDES, ISOTOPES AND SCANNERS**
Richard Baum, MD PhD
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Germany
- 4:20–4:40** **Q AND A DISCUSSION AND DAY ONE DISCUSSION BY SESSION CHAIRS**
- 4:40 – 5:30** **RECEPTION**

FRIDAY, MAY 3, 2019: DAY 2

- 8:30 – 9:50** **SESSION I: PRE-CLINICAL ADVANCES IN NETS**
- 8:30 – 8:35** **SESSION INTRODUCTION**
Chair/Panel Moderator
Matthew Meyerson, MD PhD
Dana-Farber Cancer Institute, Boston MA

- 8:35 – 8:50** **DAXX FUNCTIONS IN DEVELOPMENT, TISSUE HOMEOSTASIS, AND PANCREATIC NEUROENDOCRINE TUMOR SUPPRESSION**
Amanda Wasylishen, PhD (Gigi Lozano Lab)
University of Texas MD Anderson Cancer Center, Houston TX
- 8:50 – 9:05** **EPIGENETIC REGULATORS OF INTESTINAL ENDOCRINE CELLS AND CARCINOID TUMORS**
Pratik Singh, PhD (Ramesh Shivdasani Lab)
Dana-Farber Cancer Institute, Boston MA
- 9:05 – 9:20** **NOVEL MECHANISMS OF ACQUIRED EVEROLIMUS RESISTANCE IN PANCREATIC NEUROENDOCRINE TUMORS**
Chester Chamberlain, PhD (Michael German Lab)
University of California, San Francisco CA
- 9:20 – 9:50** **Q AND A DISCUSSION**
- 9:50 – 10:20** **COFFEE BREAK**
- 10:20 – 12:10** **SESSION II: CRACKING THE CODE**
- 10:20 – 10:25** **SESSION INTRODUCTION**
Chair/Panel Moderator
Ramesh Shivdasani, MD PhD
NETRF Board of Scientific Advisors
- 10:25 – 10:55** **LAUREN T. ERB LECTURE: NEXT-GENERATION CHARACTERIZATION OF THE CANCER CELL LINE ENCYCLOPEDIA**
William R. Sellers, MD
Broad Institute, Boston MA
- 10:55 – 11:10** **WHAT ARE THE MOLECULAR CAUSES OF SMALL INTESTINAL NEUROENDOCRINE TUMORS**
Matthew Meyerson, MD, PhD
Dana-Farber Cancer Institute, Boston MA
- 11:10 – 11:25** **THE ROLE OF ATRX/DAXX/H3.3 CHROMATIN REGULATION IN PNETS**
Laura Banaszynski, PhD
UT Southwestern Medical Center, Dallas TX
- 11:25 – 11:40** **PANCREATIC NEUROENDOCRINE NEOPLASMS: DISSECTING THE MOLECULAR HETEROGENEITY**
Kevin Yang, PhD (Sharon Gorski Lab)
Genome Sciences Centre, BC Cancer Agency, Canada
- 11:40 – 11:55** **EXPLORING THE ROLE OF SIRT6 IN PNET PROGRESSION**
Lisa Poole, PhD (Sita Kugel Lab)
Fred Hutchinson Cancer Research Center, Seattle WA

FRIDAY

- 11:55 - 12:10** **Q AND A DISCUSSION**
- 12:10 - 1:15** **LUNCH**
- 1:15 - 3:00** **SESSION III: NEW CLINICAL STRATEGIES**
- 1:15 - 1:20** **SESSION INTRODUCTION**
Chair/Panel Moderator
Chrissie Thirlwell, MD PhD FRCP
NETRF Board of Scientific Advisors
- 1:20 - 1:35** **BIOMARKERS OF RESPONSE TO CABOZANTINIB IN PATIENTS WITH NEUROENDOCRINE TUMORS**
Jennifer Chan, MD, MPH
Dana-Farber Cancer Institute, Boston MA
- 1:35 - 1:50** **NEW STRATEGIES TO IMPROVE DRUG DEVELOPMENT IN CARCINOID TUMORS**
Emily Bergsland, MD
University of California San Francisco CA
- 1:50 - 2:00** **PHASE 1 STUDY OF SAFETY AND IMMUNOGENICITY OF SURVIVIN LONG-PEPTIDE VACCINE (SURVAXM) WHEN GIVEN IN COMBINATION WITH SOMATOSTATIN ANALOGUE IN PATIENTS WITH SURVIVIN-POSITIVE METASTATIC NEUROENDOCRINE TUMORS (NETS)**
Renuka Iyer, MD
Roswell Park Cancer Center, Buffalo NY
- 2:00 - 2:10** **NET-SMART THERAPY: DEVELOPING A NEUROENDOCRINE TUMOR-TARGETED CHEMOTHERAPEUTIC**
Justin Annes, MD PhD
Stanford University Medical Center, Palo Alto CA
- 2:10 - 2:20** **Q AND A DISCUSSION**
- 2:20 - 3:00** **PANEL DISCUSSION: KEY TAKE-AWAY POINTS AND PRIORITIES FOR FUTURE RESEARCH**
NETRF Scientific Advisors and Moderators
- 3:00** **ADJOURNMENT**